Moloney Securities Asset Management LLC Has $146,000 Holdings in SOPHiA GENETICS SA (NASDAQ:SOPH)

Moloney Securities Asset Management LLC decreased its stake in SOPHiA GENETICS SA (NASDAQ:SOPH) by 41.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,500 shares of the company’s stock after selling 34,000 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in SOPHiA GENETICS were worth $146,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of SOPHiA GENETICS by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock worth $5,290,000 after acquiring an additional 86,764 shares in the last quarter. Green Alpha Advisors LLC raised its position in SOPHiA GENETICS by 119.3% in the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after purchasing an additional 25,686 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC acquired a new position in SOPHiA GENETICS in the fourth quarter worth $70,000. 31.59% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.40.

SOPHiA GENETICS Stock Down 4.4 %

NASDAQ SOPH opened at $3.68 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80. SOPHiA GENETICS SA has a 52 week low of $2.70 and a 52 week high of $7.37. The stock has a market capitalization of $240.60 million, a P/E ratio of -3.38 and a beta of 1.03. The stock has a fifty day moving average of $3.39 and a 200-day moving average of $3.55.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.